AVNS | Ticker Profile - Titan Protect

AVNS

Avanos Medical, Inc.

Healthcare · Medical Devices · NYQ

$25.05

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.2B

Total market value of the company

Trailing P/E

N/A

Forward P/E

19.83

Based on estimated future earnings — lower means cheaper

Rev Growth

+8.8%

Year-over-year revenue change

Profit Margin

-10.4%

How much profit the company keeps from each dollar of revenue

ROE

-9.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About Avanos Medical, Inc.

Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; and Trident and Esentec RFA radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. Avanos Medical, Inc. was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. The company was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

https://avanos.com

Country: United States Employees: 2,287 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.452

Positive but modest risk-adjusted returns

Kelly Fraction

0.0370

Modest edge detected — smaller position warranted

Calmar Ratio

0.220

Drawdown risk outweighs the returns — higher risk profile

Annual Return

13.2%

Historical annualised return based on price data

Max Drawdown

-59.9%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.59

Significantly more volatile than the market

52W High

$24.91

-1% below the year high

52W Low

$9.30

169% above the year low

Avg Volume

1,377,503

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

3.3%

Low short interest — limited bearish positioning

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.60

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

17.70

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.48

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

1.29

Like current ratio but excludes inventory — stricter test

Gross Margin

50.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

5.4%

Profit from core operations before interest and tax

Free Cash Flow

$17M

Positive — the business generates more cash than it spends

Revenue (TTM)

$716M

Total revenue over the last 12 months

Net Income

$-74,400,000

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go